unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet揭露微分罗格列酮和吡格列酮联合治疗的效果与n - 3脂肪酸高脂肪饮食的老鼠.pdfVIP

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet 1 1 1 1 1 1 Vladimir Kus , Pavel Flachs , Ondrej Kuda , Kristina Bardova , Petra Janovska , Michaela Svobodova , 1 1 2 2 2 Zuzana Macek Jilkova , Martin Rossmeisl , Rui Wang-Sattler , Zhonghao Yu , Thomas Illig , Jan Kopecky1* 1 Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of the Czech Republic v.v.i., Prague, Czech Republic, 2 Research Unit of Molecular ¨ Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany Abstract Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the risk of adverse side effects, which are usually associated with long-term pharmacological interventions. Our previous study in mice fed high-fat diet indicated additivity in preservation of insulin sensitivity and in amelioration of major metabolic syndrome phenotypes by the combination treatment using n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and rosiglitazone, i.e. an anti-diabetic drug of the thiazolidinedione (TZD) family. We investigated here whether pioglitazone, a TZD-drug in clinical use, could elicit the additive benefic